Oxford Biomedica, Microsoft Pact Aims At Better, Cheaper Lentiviral Vectors

Oxford Biomedica and Microsoft have joined forces to improve the yield and quality of next-generation gene therapy vectors using the cloud and machine learning, the UK gene and cell therapy company's chief business officer tells Scrip.